MedTrace Logo

SATISFY (geleSis100 Effects on AppeTIte Sensations, Feeding Behavior and Dietary energY)

NCT04257123 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2022-04-19

No results posted yet for this study

Summary

A recent clinical trial demonstrated the efficacy of Gelesis100 use for weight loss (Obes 2019;27:205-216). The present trial is designed to explore the mechanisms by which it may work, i.e. by suppressing hunger, altering food intake and/or altering the efficiency of energy extraction from food.

Conditions

  • Appetitive Behavior

Interventions

DEVICE

Gelesis100

Participants will administer Gelesis100 before lunch and dinner meals.

OTHER

Placebo

Participants will administer a placebo before lunch and dinner meals.

Sponsors & Collaborators

  • Gelesis, Inc.

    collaborator INDUSTRY

  • Purdue University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-07
Primary Completion
2020-11-30
Completion
2021-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04257123 on ClinicalTrials.gov